Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One...
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million PR Newswire VICTORIA, BC, Oct. 31, 2024 VICTORIA, BC, Oct. 31, 2024 /PRNewswire/...
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 PR Newswire VICTORIA, BC, Oct. 28, 2024 VICTORIA, BC, Oct. 28, 2024 /PRNewswire/...
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis PR Newswire VICTORIA, BC, Oct. 15, 2024 Publication...
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 PR Newswire VICTORIA, BC, Oct. 10, 2024 VICTORIA, BC, Oct. 10, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...
Eupraxia Pharmaceuticals Strengthens Senior Management Team PR Newswire VICTORIA, BC, Oct. 2, 2024 VICTORIA, BC, Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.4 | -8.33333333333 | 4.8 | 4.89 | 4.13 | 14155 | 4.55977152 | CS |
| 4 | -0.05 | -1.12359550562 | 4.45 | 5.45 | 3.89 | 27535 | 4.60846979 | CS |
| 12 | 0.99 | 29.0322580645 | 3.41 | 5.45 | 3.07 | 31778 | 4.12373102 | CS |
| 26 | 0.7 | 18.9189189189 | 3.7 | 5.45 | 3.07 | 23588 | 3.917439 | CS |
| 52 | -2.06 | -31.8885448916 | 6.46 | 7.64 | 3.07 | 32998 | 4.33149843 | CS |
| 156 | 2.4 | 120 | 2 | 9.1 | 0.8 | 27650 | 4.25502016 | CS |
| 260 | -3.35 | -43.2258064516 | 7.75 | 9.1 | 0.8 | 25233 | 4.23533796 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
